Voss SD - Search Results

1

Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain.

Voss SD, Leary TP, Sondel PM, Robb RJ. Voss SD, et al. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2428-32. doi: 10.1073/pnas.90.6.2428. Proc Natl Acad Sci U S A. 1993. PMID: 7681595 Free PMC article.

2

Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R.

Voss SD, Sondel PM, Robb RJ. Voss SD, et al. J Exp Med. 1992 Aug 1;176(2):531-41. doi: 10.1084/jem.176.2.531. J Exp Med. 1992. PMID: 1500859 Free PMC article.

3

Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression.

Bogner MP, Voss SD, Bechhofer R, Hank JA, Roper M, Poplack D, Hammond D, Sondel PM. Bogner MP, et al. Among authors: voss sd. J Immunother (1991). 1992 Feb;11(2):111-8. J Immunother (1991). 1992. PMID: 1571333

4

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.

Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM. Weil-Hillman G, et al. Among authors: voss sd. Cancer Res. 1990 May 1;50(9):2683-91. Cancer Res. 1990. PMID: 1691679

5

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.

Voss SD, Robb RJ, Weil-Hillman G, Hank JA, Sugamura K, Tsudo M, Sondel PM. Voss SD, et al. J Exp Med. 1990 Oct 1;172(4):1101-14. doi: 10.1084/jem.172.4.1101. J Exp Med. 1990. PMID: 1698909 Free PMC article.

6

The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment.

Voss SD, Weil-Hillman G, Hank JA, Sosman JA, Sondel PM. Voss SD, et al. Bull N Y Acad Med. 1989 Jan;65(1):93-110. Bull N Y Acad Med. 1989. PMID: 2690996 Free PMC article. Review. No abstract available.

7

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation.

Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM. Voss SD, et al. Cancer Immunol Immunother. 1989;29(4):261-9. doi: 10.1007/BF00199214. Cancer Immunol Immunother. 1989. PMID: 2787694 Free PMC article.

8

Addendum to SCID, interleukin-2, and the interleukin-2 receptor review.

Sondel PM, Voss SD, Hong R. Sondel PM, et al. Among authors: voss sd. Blood. 1994 Jul 15;84(2):667-8. Blood. 1994. PMID: 8025293 Free article. No abstract available.

9

Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells.

Kaur I, Voss SD, Gupta RS, Schell K, Fisch P, Sondel PM. Kaur I, et al. Among authors: voss sd. J Immunol. 1993 Mar 1;150(5):2046-55. J Immunol. 1993. PMID: 8094731

10

Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way.

Voss SD, Hong R, Sondel PM. Voss SD, et al. Blood. 1994 Feb 1;83(3):626-35. Blood. 1994. PMID: 8298124 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters